Clinical outcomes of pembrolizumab therapy in advanced‐NSCLC patients with poor performance status (≥3) and high PD‐L1 expression (TPS ≥50%): A case series

Pembrolizumab is the standard first‐line treatment for advanced non‐small cell lung cancer (NSCLC) with programmed death‐ligand 1 (PD‐L1) expression tumor proportion score (TPS) ≥50%. The benefit of pembrolizumab in patients with advanced NSCLC and poor performance status (PS ≥3) is limited, even wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Inaba‐Higashiyama, Ryoko, Yoshida, Tatsuya, Jo, Hitomi, Shirasawa, Masayuki, Motoi, Noriko, Ohe, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705620/
https://www.ncbi.nlm.nih.gov/pubmed/33085191
http://dx.doi.org/10.1111/1759-7714.13713
_version_ 1783616981299101696
author Inaba‐Higashiyama, Ryoko
Yoshida, Tatsuya
Jo, Hitomi
Shirasawa, Masayuki
Motoi, Noriko
Ohe, Yuichiro
author_facet Inaba‐Higashiyama, Ryoko
Yoshida, Tatsuya
Jo, Hitomi
Shirasawa, Masayuki
Motoi, Noriko
Ohe, Yuichiro
author_sort Inaba‐Higashiyama, Ryoko
collection PubMed
description Pembrolizumab is the standard first‐line treatment for advanced non‐small cell lung cancer (NSCLC) with programmed death‐ligand 1 (PD‐L1) expression tumor proportion score (TPS) ≥50%. The benefit of pembrolizumab in patients with advanced NSCLC and poor performance status (PS ≥3) is limited, even when the tumor is PD‐L1‐expression‐positive. We retrospectively reviewed a total of four NSCLC cases with high PD‐L1 expression (TPS ≥50%) and poor PS. The only patient with very high PD‐L1 expression (TPS 100%) responded to pembrolizumab, but none of the three patients with high PD‐L1 expression (50%–80%) responded to pembrolizumab. In conclusion, pembrolizumab can serve as a treatment option for patients with poor PS, if PD‐L1 expression TPS is 100%.
format Online
Article
Text
id pubmed-7705620
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-77056202020-12-09 Clinical outcomes of pembrolizumab therapy in advanced‐NSCLC patients with poor performance status (≥3) and high PD‐L1 expression (TPS ≥50%): A case series Inaba‐Higashiyama, Ryoko Yoshida, Tatsuya Jo, Hitomi Shirasawa, Masayuki Motoi, Noriko Ohe, Yuichiro Thorac Cancer Case Reports Pembrolizumab is the standard first‐line treatment for advanced non‐small cell lung cancer (NSCLC) with programmed death‐ligand 1 (PD‐L1) expression tumor proportion score (TPS) ≥50%. The benefit of pembrolizumab in patients with advanced NSCLC and poor performance status (PS ≥3) is limited, even when the tumor is PD‐L1‐expression‐positive. We retrospectively reviewed a total of four NSCLC cases with high PD‐L1 expression (TPS ≥50%) and poor PS. The only patient with very high PD‐L1 expression (TPS 100%) responded to pembrolizumab, but none of the three patients with high PD‐L1 expression (50%–80%) responded to pembrolizumab. In conclusion, pembrolizumab can serve as a treatment option for patients with poor PS, if PD‐L1 expression TPS is 100%. John Wiley & Sons Australia, Ltd 2020-10-21 2020-12 /pmc/articles/PMC7705620/ /pubmed/33085191 http://dx.doi.org/10.1111/1759-7714.13713 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Inaba‐Higashiyama, Ryoko
Yoshida, Tatsuya
Jo, Hitomi
Shirasawa, Masayuki
Motoi, Noriko
Ohe, Yuichiro
Clinical outcomes of pembrolizumab therapy in advanced‐NSCLC patients with poor performance status (≥3) and high PD‐L1 expression (TPS ≥50%): A case series
title Clinical outcomes of pembrolizumab therapy in advanced‐NSCLC patients with poor performance status (≥3) and high PD‐L1 expression (TPS ≥50%): A case series
title_full Clinical outcomes of pembrolizumab therapy in advanced‐NSCLC patients with poor performance status (≥3) and high PD‐L1 expression (TPS ≥50%): A case series
title_fullStr Clinical outcomes of pembrolizumab therapy in advanced‐NSCLC patients with poor performance status (≥3) and high PD‐L1 expression (TPS ≥50%): A case series
title_full_unstemmed Clinical outcomes of pembrolizumab therapy in advanced‐NSCLC patients with poor performance status (≥3) and high PD‐L1 expression (TPS ≥50%): A case series
title_short Clinical outcomes of pembrolizumab therapy in advanced‐NSCLC patients with poor performance status (≥3) and high PD‐L1 expression (TPS ≥50%): A case series
title_sort clinical outcomes of pembrolizumab therapy in advanced‐nsclc patients with poor performance status (≥3) and high pd‐l1 expression (tps ≥50%): a case series
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705620/
https://www.ncbi.nlm.nih.gov/pubmed/33085191
http://dx.doi.org/10.1111/1759-7714.13713
work_keys_str_mv AT inabahigashiyamaryoko clinicaloutcomesofpembrolizumabtherapyinadvancednsclcpatientswithpoorperformancestatus3andhighpdl1expressiontps50acaseseries
AT yoshidatatsuya clinicaloutcomesofpembrolizumabtherapyinadvancednsclcpatientswithpoorperformancestatus3andhighpdl1expressiontps50acaseseries
AT johitomi clinicaloutcomesofpembrolizumabtherapyinadvancednsclcpatientswithpoorperformancestatus3andhighpdl1expressiontps50acaseseries
AT shirasawamasayuki clinicaloutcomesofpembrolizumabtherapyinadvancednsclcpatientswithpoorperformancestatus3andhighpdl1expressiontps50acaseseries
AT motoinoriko clinicaloutcomesofpembrolizumabtherapyinadvancednsclcpatientswithpoorperformancestatus3andhighpdl1expressiontps50acaseseries
AT oheyuichiro clinicaloutcomesofpembrolizumabtherapyinadvancednsclcpatientswithpoorperformancestatus3andhighpdl1expressiontps50acaseseries

Ejemplares similares